Helicobacter pylori infection influences nocturnal gastric acid breakthrough

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 8, 2000, Pages 1049-1056

  Katsube, T ^a   Adachi, K ^a   Kawamura, A ^a   Amano, K ^a   Uchida, Y ^a   Watanabe, M ^a   Kinoshita, Y ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RABEPRAZOLE; STOMACH SECRETION INHIBITOR; UREA;

ADULT; AMBULATORY MONITORING; ARTICLE; BREATH ANALYSIS; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; JAPAN; MALE; NIGHT; PH MEASUREMENT; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CIRCADIAN RHYTHM; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE;

EID: 0033859704     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00799.x     Document Type: Article

References (36)

1. 1 Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999; 13(S3): 3-10.
2. 2 Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: 22-37.
3. 3 T. J. Humphries & the European Rabeprazole Study Group. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 49-57.
4. 4 Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33: 118-24.
5. 5 Leite LP, Johnston BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91: 1527-31.
6. 6 Katzka DA, Paoletti V, Leite L, Castell DO. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy. Am J Gastroenterol 1996; 91: 2110-3.
7. 7 Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
8. 8 Robertson D, Aldersley M, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut 1987; 28: 1484-8.
9. 9 Klinkenberg-knol EC, Meuwissen SGM. Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther 1990; 4: 485-95.
10. 10 Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992; 51: 59-67.
11. 11 Hatlebakk JG, Berstad A. Endoscopic grading of reflux oesophagitis: what observations correlate with gastrooesophageal reflux? Scand J Gastroenterol 1997; 32: 760-5.
12. 12 William CO, Lawrence FJ. Responses to different levels of esophageal acidification during waking and sleep. Dig Dis Sci 1998; 43: 241-5.
13. 13 Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Aliment Pharmacol Ther 1994; 89: 989-91.
14. 14 Katz OP, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231-4.
15. 15 Fouad YM, Katz PO, Castell DO. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999; 13: 1467-71.
16. 16 Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992; 102: 760-6.
17. 17 Haruma K, Goto T, Kawaguchi H, et al. Marked decrease of H. pylori infection in asymptomatic children in Japan. Gastroenterology 1996; 110: A130(Abstract).
18. 18 Kinoshita Y, Kawanami C, Kishi K, et al. H. pylori independent chronological change of gastric acid secretion in Japanese. Gut 1997; 41: 1-7.
19. 19 Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-43.
20. 20 Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effects of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-32.
21. 21 Gillen D, Wirz AA, Neithercut WD, Ardill JES, McColl KEL. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999; 44: 468-75.
22. +-ATPase vesicles isolated from hog gastric mucosa. Biochem J 1990; 29: 701-6.
23. +-ATPase. Biochem Biophys Res Commun 1990; 167: 754.
24. +-ATPase: the site of action of omeprazole. Scand J Gastroenterol 1989; 24: 3-11.
25. 25 Chiverton SG, Howden CW, Burget DW, Hunt RH. Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther 1992; 6: 103-11.
26. 26 Hongo M, Ohara S, Hirasawa Y, et al. Effect of lansoprazole on intragastric pH: comparison between morning and evening dosing. Dig Dis Sci 1992; 37: 882-90.
27. 27 Rokkas T, Sladen E. Ambulatory esophageal pH recording in gastroesophageal reflux: relevance to the development of esophagitis. Am J Gastroenterol 1988; 83: 629-32.
28. 28 Satoh K, Kimura K, Yoshida Y, et al. Relationship between Helicobacter pylori and atrophic gastritis. Eur J Gastroenterol Hepatol 1994; 6: S85-8.
29. 29 Kuipers EJ, Lee A, Klinkenberg KEC, Meuwissen SG. Review article: the development of atrophic gastritis - Helicobacter pylori and the effects of acid suppressive therapy. Aliment Pharmacol Ther 1995; 9: 331-40.
30. 30 Schlemper RJ, Van der Werf SDJ, Vandenbroucke JP, Biemond I, Lamers CBHW. Seroepidemiology of gastritis in Japanese and Dutch working populations: evidence for the development of atrophic gastritis that is not related to Helicobacter pylori. Gut 1995; 37: 199-204.
31. 31 Mihara M, Haruma K, Kodama T, et al. Low prevalence of Helicobacter pylori infection in patients with reflux esophagitis. Gut 1996; 39(S2): A94.
32. 32 Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
33. 33 Ishizaki T, Horai Y. Review article: cytocrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13(S3): 27-36.
34. 34 Hendel J, Hendel L, Aggestrup S. Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease? Aliment Pharmacol Ther 1995; 9: 693-7.
35. 35 Hatlebakk PO, Katz BK, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235-40.
36. 36 Peghini PL, Katz PO, Castell DO. Ranitidine control nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.